David Smith Net Worth

The estimated Net Worth of David Ross Smith is at least 20.2 百万$ dollars as of 3 March 2022. Mr. Smith owns over 8,965 units of Charles River Laboratories International stock worth over 6,733,835$ and over the last 9 years he sold CRL stock worth over 9,988,065$. In addition, he makes 3,507,300$ as Chief Financial Officer、 Corporate Executive Vice President at Charles River Laboratories International.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Smith CRL stock SEC Form 4 insiders trading

David has made over 35 trades of the Charles River Laboratories International stock since 2017, according to the Form 4 filled with the SEC. Most recently he exercised 8,965 units of CRL stock worth 1,224,619$ on 3 March 2022.

The largest trade he's ever made was exercising 16,817 units of Charles River Laboratories International stock on 2 January 2018 worth over 865,235$. On average, David trades about 2,430 units every 30 days since 2015. As of 3 March 2022 he still owns at least 34,784 units of Charles River Laboratories International stock.

You can see the complete history of Mr. Smith stock trades at the bottom of the page.

David Smith biography

David Ross Smith serves as Chief Financial Officer, Corporate Executive Vice President of the Company. He has served as our Corporate Executive Vice President and Chief Financial Officer since August 2015. He joined us as Corporate Vice President, Discovery Services through our acquisition of Argenta and BioFocus from Galapagos NV in March 2014 and was promoted to Corporate Senior Vice President, Global Discovery Services, in October 2014. At Galapagos, he served in various capacities, including as Chief Executive Officer of its Galapagos Services division and as Chief Financial Officer. Mr. Smith served as Chief Financial Officer for Cambridge University Hospitals from 2007 to 2013. Mr. Smith spent eight years at PricewaterhouseCoopers prior to joining AstraZeneca in 1997, where he spent the next nine years in various finance and business roles of increasingly greater responsibility.

What is the salary of David Smith?

As the Chief Financial Officer、 Corporate Executive Vice President of Charles River Laboratories International, the total compensation of David Smith at Charles River Laboratories International is 3,507,300$. There are 1 executives at Charles River Laboratories International getting paid more, with James Foster having the highest compensation of 17,722,100$.

How old is David Smith?

David Smith is 54, he's been the Chief Financial Officer、 Corporate Executive Vice President of Charles River Laboratories International since 2017. There are 16 older and 5 younger executives at Charles River Laboratories International. The oldest executive at Charles River Laboratories International Inc. is Stephen Chubb, 76, who is the Independent Director.

Insiders trading at Charles River Laboratories International

Over the last 22 years, insiders at Charles River Laboratories International have traded over 220,588,205$ worth of Charles River Laboratories International stock and bought 18,392 units worth 3,841,397$ . The most active insiders traders include James C Foster、Richard F Wallman、David P Johst. On average, Charles River Laboratories International executives and independent directors trade stock every 14 days with the average trade being worth of 2,223,188$. The most recent stock trade was executed by Joseph W La Plume on 8 August 2024, trading 1,780 units of CRL stock currently worth 354,861$.

What does Charles River Laboratories International do?

charles river provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. #drugdiscovery #biotech #biotechnology #pharmaceuticals #cro

Complete history of Mr. Smith stock trades at Charles River Laboratories International

Charles River Laboratories International executives and stock owners

Charles River Laboratories International executives and other stock owners filed with the SEC include:

• James Foster,
  Chairman of the Board, President, Chief Executive Officer
• David Smith,
  Chief Financial Officer, Corporate Executive Vice President
• James C. Foster,
  Chairman, CEO & Pres
• Joseph LaPlume,
  Corporate Executive Vice President, Corporate Development and Strategy
• Birgit Girshick,
  Corporate Executive Vice President, Global Discovery and Safety Assessment, Biologics and Avian
• William Barbo,
  Corporate Executive Vice President and Chief Commercial Officer
• David Ross Smith,
  Corp. Exec. VP & CFO
• William D. Barbo,
  Chief Commercial Officer & Corp. Exec. VP
• Joseph W. LaPlume,
  Corp. Exec. VP of Corp. Devel. & Strategy
• Birgit Girshick,
  Corp. Exec. VP & COO
• George Milne,
  Lead Independent Director
• George Massaro,
  Independent Director
• Robert Bertolini,
  Independent Director
• Richard Reese,
  Independent Director
• Richard Wallman,
  Independent Director
• Martin Mackay,
  Independent Director
• Deborah Kochevar,
  Independent Director
• Jean-Paul Mangeolle,
  Independent Director
• Stephen Chubb,
  Independent Director
• Virginia Wilson,
  Independent Director
• Nancy Andrews,
  Independent Director
• George Llado,
  Director
• Matthew L. Daniel,
  Corp. Sr. VP, Gen. Counsel, Corp. Sec. & Chief Compliance Officer
• Todd Spencer,
  Corp. VP of Investor Relations
• Mark Mintz,
  Corp. Sr. VP & Chief Information Officer
• Prof. Julie Frearson Ph.D.,
  Corp. Sr. VP & Chief Scientific Officer
• Michael Gunnar Knell,
  Corp. Sr. VP & Chief Accounting Officer
• John J Crowley,
  SVP, Chief Accounting Officer
• Davide Molho,
  Corporate Executive VP
• Michael Gunnar Knell,
  CSVP&Chief Accounting Officer
• Craig B. Thompson,
  Director
• John W Kuo,
  CEVP General Counsel & CCO
• Victoria L Creamer,
  EVP & Chief People Officer
• David P Johst,
  Corporate Executive VP
• Jorg Geller,
  OFFICERS
• Nancy Gillett,
  Vice President
• Thomas F Ackerman,
  Sr. Vp and CFO
• Samuel O Md Thier,
  Director
• William Waltrip,
  Director
• Nancy T Chang,
  Director
• Christopher Berthoux,
  OFFICERS
• Douglas E Rogers,
  Director
• Real H Renaud,
  Executive Vice President
• Brian Bathgate,
  Corporate Vice President
• Joanne P Acford,
  Corp. Sr VP, GC and Corp. Sec
• David J Elliott,
  Officer
• Linda Mc Goldrick,
  Director
• Stephanie B Wells,
  Senior Vice President
• Cheri L Walker,
  Corporate Senior VP
• Nicholas Ventresca,
  Senior Vice President
• Michael F Ankcorn,
  Corporate Sr. Vice President
• Walter S Nimmo,
  Director
• S Louise Mccrary,
  Director
• John C Ho,
  Senior Vice President
• Alastair Stuart Mcewan,
  Corporate Vice President
• John Urquhart,
  Director
• Dennis R Shaughnessy,
  Sr. VP Corporate Development
• Robert Cawthorn,
  Director
• Flavia Pease,
  Corporate Executive VP & CFO
• Shannon M Parisotto,
  CEVP, Disc & Safety Assessment
• Reshema Kemps Polanco,
  Director